Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report 2023-01-31 20:25
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy 2023-01-09 23:25
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) 2023-01-06 20:25
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum 2023-01-03 23:25
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office 2022-12-29 23:25
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting 2022-11-07 23:25
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting 2022-10-26 19:25
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy 2022-10-13 22:25
Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders 2022-09-26 19:25
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy 2022-09-20 19:25
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe 2022-08-25 19:25
Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report 2022-07-22 19:25
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy 2022-07-06 23:00
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy 2022-06-23 23:00
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy 2022-06-02 20:00
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom 2022-04-27 19:40
Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting 2022-04-07 09:34
Alterity Therapeutics to Present at the 34th Annual Roth Conference 2022-03-07 20:59
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease 2022-01-28 20:08
Appendix 4C - Q2 FY22 Quarterly Cash Flow Report 2022-01-27 20:45
1 2 3